



of sub Saharan Africa

Eosinophilic Esophagitis

Dr. Hassan Ali WITS University CMJAH/ Med GI April 2024

Contents

- Introduction
- Eosinophilic Esophagitis
 - Pathogenesis
 - Clinical presentation
 - Diagnosis
 - Treatment
 - Complications

- Other Causes
 - GERD
 - Pills Esophagitis
 - Infectious Esophagitis
 - Radiation Esophagitis

Based on the British Society of Gastroenterology Guidelines, 2022

Introduction

• **Esophagitis** is general term refers to inflammation that occurs due to injury or irritation to the esophageal mucosa

• There are many causes of esophagitis and essentially the presentation is similar which include **retrosternal chest**, heartburn, **dysphagia or odynophagia**

Eosinophilic Esophagitis (EoE)

• **Difinition**: Chronic immune mediated or antigen mediated esophageal disease characterised by symptoms related to esophageal dysfunction and eosinophil predominant mucosal inflammation

Epidemiology

• **Prevalence** in developed countries is between 45 and 55 cases per 100,000 population

• **EoE** is a disease of cold climate with wide range of age disrtibution at presentation. More common among the white ethnicity and in male

Pathophysiology

• **EoE** is a disease with a complex genetic cause and inheritance is due to the effects of multiple genetic loci that increase disease risk in the context of environmental and host immune factors.


Journal of Allergy and Clinical Immunology

Volume 147, Issue 1, January 2021, Pages 255-266

Food allergy and gastrointestinal disease **Replication and meta**analyses nominate numerous eosinophilic esophagitis risk genes



Replication and Meta-Analyses Nominate Numerous Eosinophilic Esophagitis Risk Genes






eQTL: Expression quantitative trait loci


Role of Mast Cells in EoE

GRAPHICAL ABSTRACT



Capsule summary: A machine learning protocol for identifying mast cells, designated Mast Cell–Artificial Intelligence, readily identified spatially distinct and dynamic populations of mast cells in eosinophilic esophagitis, providing a platform to better understand this cell type in eosinophilic esophagitis and other diseases.

Pathophysiology



Clinical Presentation

- Food bolus **impaction** (may be masked by compensating behaviours) 46%
- **Dysphagia** 7.3% and in 22% of patients with non obstructive dysphagia
- **Reflux** symptoms 7.7%
- Non cardiac **chest pain** 6%

Diagnosis

• Good clinical history

• Good esophageal endoscopic examination

• Proper esophageal **biopsies**

• Histological examination

Clinical history

- Imbibing fluids with meals to lubricate foods
- Modifying food (cutting into small pieces)
- Prolonged meal times
- Avoidance of hard textured foods
- Chewing excessively
- Turning away pills

The IMPACT acronym


Young age, male, dysphagia and food allergies

Esophageal Endoscopic Examination


- Esophageal rings
- Edema
- Furrows
- Strictures
- Exudates

Normal findings do not exclude diagnosis

EREFS Score



Esophageal Biopsies




Endoscopy and Biopsies to Exclude EoE in Patients with GERD Symptoms Refractory to PPI Usually Not Indicated

Histology

- **Stop** PPI prior to endoscopy and biopsy for at least 3 weeks
- Mucosal Eosinophils (≥15 per 0.3 mm2) is diagnostic
- Other histological features of EoE (eg: basal cell hyperplasia, oedema, microabscesses, eosinophil layering, eosinophil degranulation and subepithelial sclerosis)
- **Re-scope** patients with high index of suspicion if the initial histology was not diagnostic

Histological Appearance



Other

Causes of Esophageal Eosinophilia

Condition			
Gastro-oesophageal reflux disease			
Achalasia			
Eosinophilic gastroenteritis or colitis with eosinophilic oesophagitis			
Infection (fungal or viral)			
Pill oesophagitis			
Hyper-eosinophilic syndrome			
Drug hypersensitivity reactions			
Connective Tissue diseases			

Eosinophilia in the oesophagus is rare and data for an eosinophil density of $\geq 15/0.3$ mm² for causes other than eosinophilic oesophagitis is limited.

Eosinophilic Esophagitis and GERD

- Can **coexist** in the same patient
- EoE that responds clinically to a PPI is **the same** disease as EoE that fails to respond to a PPI

Treatment of Eosinophilic Esophagitis

- **Goal:** Induce long-term clinical and histological remission
- **Symptoms** degree **do not** reflect histological status
- Treatment Options:

Medical - Dietary - Endoscopic

- **Proton Pump Inhibitor** monotherpy is widely practiced as **first line treatment**
- Dose: **40 mg** omeprazole daily or equivalent, should be given twice for **8-12** ws before assessing response
- Appears effective in maintaining **remission**
- high risk of **relapse** on stopping therapy

- **Topical Steroids:** Effective for **inducing** histological and clinical remission
- Likely reduce the development of **strictures**
- **Relapse** is high after withdrawal, maintenance treatment is recommended
- Systemic steroids **are not** recommended

Efficacy of Steroids

Clinical Gastroenterology and Hepatology

Volume 18, Issue 13, December 2020, Pages 2903-

2911.e4

Original Article

Alimentary Tract

Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice

Conclusions

In an analysis of data from a large cohort of patients with EoE in Europe, we found topical steroids to be the most effective at inducing clinical and histologic remission, but PPIs to be the most frequently prescribed. Treatment approaches vary with institution and presence of fibrosis or strictures.

Drug class	Adults and adolescents (≥ 12 yr)
Proton pump inhibitors	 Induction: twice daily (e.g., pantoprazole 40 mg twice daily) Maintenance: once or twice daily (e.g., pantoprazole 40 mg daily or twice daily)
Topical corticosteroids*	
Orodispersable tablets	 Induction: 1 mg twice daily Maintenance: 0.5–1 mg twice daily (children < 18 yr not approved)
Inhalers (e.g., fluticasone propionate)†	 Induction: 1–2 mg twice daily Maintenance: 250 μg–1 mg twice daily or 1 mg at bedtime
Slurry (e.g., budesonide slurry)‡	 Induction: 1 mg twice daily Maintenance: 0.25–1 mg twice daily

• Novel Biologics that used in other allergic conditions (such as Dupilumab, Cendakimab and Benralizumab) have shown promise

- BSG not recommend
 - Monoclonal Antibody Therapies
 - Immunomodulators
 - Sodium Cromoglycate
 - Montelukast
 - Antihistamines

Diet Treatment

- Elimination diets are **effective** in achieving clinicohistological **remission**
- Dietitian support is strongly recommended
- Exclusive elemental diets have a **limited** role
- Milk, Wheat, Soy, Eggs, Nuts and Fish

Elimination Diets

Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis



Christoph Mayerhofer,¹ Anna Maria Kavallar,¹ Denise Aldrian,¹ Andrea Katharina Lindner,² Thomas Müller,¹ and Georg Friedrich Vogel^{1,3}

¹Department of Paediatrics I, Medical University of Innsbruck, Innsbruck, Austria; ²Department of Urology, Medical University Innsbruck, Innsbruck, Austria; and ³Institute of Cell Biology, Medical University of Innsbruck, Innsbruck, Austria

34 studies,	, 1762 patients	Diet type	N	Efficacy
		SFED	701	61.3% (95%-CI: 53.0-69.3%)
> 15/HPF	FFED	302	49.4% (95%-CI: 32.5-66.3%)	
		OFED	306	51.4% (95%-CI: 42.6-60.1%)
	1	TED	453	45.7% (95%-CI: 32.0-59.7%)
SFED	TED 0	\rightarrow		
				Clinical Gastroenterology and Hepatology

Endoscopic Treatment

- Endoscopic dilatation is **effective** in improving symptoms in patients with fibrostenotic disease
- Endoscopic dilatation is **safe** in patients with eosinophilic esophagitis and can be performed using either **balloon** or **bougie** dilators
- Better outcome if therapeutic dilatation is **combined** with effective antiinflammatory therapy such as topical **steroids**

Treatment of Refractory and Recurrence

- **Refractory** EoE should be **jointly managed** by a gastroenterologist and allergy specialist to optimise treatment
- **Recurrence** while on treatment manage by **repeating** endoscopy for assessment and to obtain tissue for histology

Complications

- Strictures and narrow lumen esophagus (commonly underestimated)
- Treatment: Endoscopic dilatation is **recommended** with better out come when combined with topical steroid
- Targeted size is 16 to 18mm, recommended to be done gradually and in more than one session

Complications

- **Perforation:** EoE is the **most** common cause of spontaneous perforation of the oesophagus
- CT chest with contrast to assess the **degree** of extravasations
- Limited extravasations (<3 cms) should be drained by an endoscopically placed drain and with esophageal stenting for slow healing tear

Complications


Anxiety and depression

• Due to persistent symptoms and social restrictions and is alleviated by effective therapy


Drugs side effects

- PPI side effects (diarrhoea, gastrointestinal infections or magnesium deficiency), then consider switching to alternative treatments such as diet or topical steroid
- Steroid side effects eg: candida infection ,Treated with topical antifungal while continuing steroid


Proposed Management Algorithm



Proposed Management Algorithm



Proposed Management Algorithm




Other Causes of Esophagitis

Differential Diagnosis

- All other causes of esophagitis.
- Symptoms are very **similar** among this group
- Retrosternal chest pain, Odynophagia, Heart pain and Dysphagia are **the main** presenting symptoms
- Detailed workup is very **essential** for diagnosis

Reflux Esophagitis

- Erosive Esophagitis due to the reflux of gastric contents
- **Symptoms:** Heart burn, Non cardiac chest pain and Regurgitation are the disease defining symptoms
- **Diagnosis:** History, OGD and PH study
- **Treatment:** PPI and life style modification



Medication Induced Esophagitis

- Esophageal mucosa injury due to direct toxic effect of pills
- Prolong pills contact can cause direct irritant effect and disruption of mucosal cytoprotective barriers
- **Symptoms:** Dysphagia, Odynophagia and Retrosternal Chest Pain
- **Diagnosis:** History and OGD



Medication Induced Esophagitis

- Medications: NSAIDs, Tetracycline, Clindamycin, Doxacycline, Bisphosphonates, Potasium chloride and Ferrous Sulphate
- **Treatment:** Supportive. Offending drug can be restarted after complete resolution of symptoms

Patient-related

- Geriatric age group
- Bedridden
- Decreased salivation
- Ingestion of medications while supine
- Inadequate fluid intake when ingesting drugs
- Polypharmacy

Pathological (delayed esophageal or gastric emptying)

- Esophageal motility disorders
- Extrinsic compression (eg, abnormal vasculature, mass)
- Gastroesophageal reflux disease
- Impaired acid clearance
- Left atrial enlargement
- Thoracic surgery

Drug-related

- Chemical structure
- Formulation of pill
- Solubility characteristics
- Caustic characteristics of agents (acidic or alkaline)
- Osmolality
- Pill size
- Pill shape

Infectious Esophagitis

- **Causes:** Bacteria, Viruses, Fungal and Parasitic microorganisms with the least common being bacteria and the most **common** being fungal
- **Pathophysiology:** Involves **colonization** with mucosal adherence and **proliferation**. The second step involves **impairing** the host defense mechanisms
- Risk Factors: Immunocompromized patients

Fungal Esophagitis "Candidiasis"

- Endoscopic signs: Small, diffuse, linear, yellow-white, cheese-like plaques adherent to the mucosa
- **Diagnosis:** OGD/ Histology
- **Treatment:** Fluconazole 200mg stat, then 100mg daily for 2ws. Ketoconazole 200mg daily for 2ws



Viral Esophagitis

- Herpes simplex virus (HSV) is the **most common** cause of viral esophagitis. It infects the squamous epithelium leading to vesicles and then ulcerations
- Cytomegalovirus (CMV), Epstein-Barr (EBV) and varicella-zoster (VZV) are other viral causes of viral esophagitis

HSV vs CMV

Endoscopic appearance: HSV esophagitis results in multiple small, deep ulcerations. Biopsy: Edges of ulcer

Histology: Multinucleated giant cells with ballooning and degeneration squamous cells with inclusion is pathognomonic for diagnosis

Treatment: Oral or intravenous acyclovir. Foscarnet for those who are non-responders


Endoscopic appearance: CMV esophagitis is characterized by several large, shallow, superficial ulcerations. **Biopsy:** Center of ulcer

Histology: Large cells with both intracytoplasmic inclusions and amphophilic intranuclear inclusions are seen in CMV esophagitis.

Treatment: CMV esophagitis is treated with Gancyclovir or Valganciclovir


HSV vs CMV






Endoscopy image demonstrating a single, large linear ulcer (black arrow).


Histological Appearance of Candida, HSV and CMV



B) HSV1/2 immunohistochemical stain demonstrating nuclear and granular cytoplasmic positivity in infected cells.




A) GMS stain demonstrating numerous yeast forms including pseudohyphae (arrows) consistent with *Candida* species.



C) CMV immunohistochemical stain demonstrating intranuclear and cytoplasmic positivity in infected cells.

Radiation Induced Esophagitis

- Pathophysiology:
 Involves DNA damage
 and cell death from
 high-energy electrons
- Complications: strictures, ulceration, fistula and perforation



THANK YOU